BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer.
The tumor suppressor gene BRCA1 on chromosome 17q21 has been characterized and shown to be mutated in patients with familial breast and ovarian cancer. Several studies examined the relatives of women with breast cancer and noted an association with ovarian and prostate cancer. This study investigated 24 human prostate cancer specimens for BRCA1 gene mutations and loss of heterozygosity (LOH) on chromosome 17q21 assessed by the polymerase chain reaction. LOH was identified using 7 highly polymorphic tandem repeat markers on chromosome 17q21, in addition to an analysis of the whole coding region of the BRCA1 gene. Four of the 24 prostate cancer specimens showed LOH at one or more loci, all of which were histologically poorly differentiated (4 of 11) and stage D (4 of 15). One of the 24 cases showed a germ-line mutation of the BRCA1 gene, and a sister of this patient died of ovarian cancer. It appears that the BRCA1 gene is not frequently involved in the development of primary prostate cancer.
Uchida
T
T
Department of Urology, University of Kitasato Hospital, Sagamihara, Kanagawa, Japan. tuchida@green.ocn.ne.jp
Wang
C
C
Sato
T
T
Gao
J
J
Takashima
R
R
Irie
A
A
Ohori
M
M
Koshiba
K
K
D019313:BRCA1 Protein / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17; D006801:Humans; D019656:Loss of Heterozygosity; D008297:Male; D009154:Mutation; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011471:Prostatic Neoplasms / Q000235:genetics*; D017422:Sequence Analysis, DNA